Following a re-examination, the European Medicines Agency’s human health committee, CHMP confirmed its initial recommendation to refuse the granting of a conditional marketing authorization for Masitinib AB Science’s masitinib. 18 October 2024
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
In the UK, drug developers and other stakeholders have until October 13, 2021 to provide input on proposed changes to the health technology assessment (HTA) methods used by the country’s HTA body. 19 August 2021
Amid a shortage of vaccines in India, Hyderabad-based public sector undertaking, Indian Immunologicals Limited (IIL) has produced a drug substance to boost the production of Bharat Biotech's vaccine Covaxin. 19 August 2021
Partners Boehringer Ingelheim and Eli Lilly have announced that Jardiance (empagliflozin) 10mg has been approved by the US Food and Drug Administration (FDA) to reduce the risk of cardiovascular death plus hospitalization for heart failure in adults with heart failure with reduced ejection fraction (HFrEF). 19 August 2021
Shares of Danish CNS specialist Lundbeck closed down 6.9% at 184.45 kroner yesterday as it posted financials for the first half of 2021. 19 August 2021
Otsuka Pharmaceutical yesterday announced top-line outcomes from a Phase II clinical trial that evaluated the safety and efficacy of brexpiprazole for the treatment of patients with borderline personality disorder (BPD), that did not meet the primary endpoint, change from baseline in the Zanarini Rating Scale for BPD. 19 August 2021
Artificial intelligence-driven pharma company Exscientia has taken another step forward in a major collaboration with New York’s Bristol Myers Squibb. 18 August 2021
Boston, USA-based start-up Jnana Therapeutics today announced the closing of a $50 million Series B financing, led by RA Capital Management, and included all existing investors, including Polaris Partners, Versant Ventures, Avalon Ventures, AbbVie Ventures and Pfizer Ventures. 18 August 2021
In the UK, a consortium of public and private companies have been awarded part of a £53 million ($73 million) grant from UK Research and Innovation (UKRI) and the Made Smarter initiative. 18 August 2021
For many years, industry commentators have observed that there could be huge untapped therapeutic potential for psychedelics, should the correct development pathways be found. 18 August 2021
For many years, artificial intelligence (AI), in particular machine learning, have been touted as potentially transformational technologies for drug discovery and development. 16 August 2021
Tokyo-based drugmaker Eisai has announced the Japanese launch of Tazverik Tablets 200mg (tazemetostat hydrobromide) for relapsed or refractory EZH2 gene mutation-positive follicular lymphoma, when standard treatment is not applicable. 16 August 2021
The US Food and Drug Administration has granted approval for Ticovac (tick-borne encephalitis (TBE) vaccine) for active immunization to prevent TBE in individuals 1 year of age and older. 16 August 2021
Physics-based US software specialist Schrödinger and China’s Zai Lab Limited have entered into a global discovery, development and commercialization collaboration focused on a novel program in oncology targeting DNA damage response. 16 August 2021
US President Joe Biden believes that health care is a right, not a privilege. No American should have to face difficult choices between paying for their prescription medications or other essential needs., he said, as he announced his vision for reducing the high cost of prescription drugs. 14 August 2021
As the dust settles on this year’s Alzheimer’s Association International Conference (AAIC), the industry is left with a wealth of insight from some of the leading scientists in the field - much of which will point the way for potential therapeutic breakthroughs. 13 August 2021
While the suspension of patent extensions in Brazil could lead to lower drug prices and cheaper generic drugs, this move may deter large biopharma companies from marketing innovative drugs in Brazil in the future, says data and analytics company. 13 August 2021
With private equity group Carlyle declining to increase its last offer of 155 pence a share in the bidding war for UK inhaled therapies specialist Vectura earlier this week, US tobacco and nicotine giant Philip Morris (PMI) looks set to be the winner. 13 August 2021
The US Food and Drug Administration on Thursday approved a new indication for Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution for idiopathic hypersomnia (IH) in adults. 13 August 2021